INT256248

Context Info Confidence 0.35 First Reported 2008 Last Reported 2008 Negated 0 Speculated 1 Reported most in Body Documents 1 Total Number 1 Disease Relevance 1.25 Pain Relevance 0.08

enzyme binding (Esr1) DNA binding (Esr1) protein complex (Esr1) cytoplasm (Esr1) lipid binding (Esr1) nucleus (Esr1)

Esr1 (Mus musculus)

Pain Term Frequency Confidence Heat antagonist 2 89.24 ischemia 1 74.76 aspirin 3 5.00 Inflammation 1 5.00 backache 1 5.00 Bioavailability 2 5.00 tolerance 3 5.00 headache 1 5.00

Disease Term Frequency Confidence Heat Coronary Heart Disease 6 95.84 Increased Venous Pressure Under Development 22 91.76 [[ / [[]]]] 14 84.48 Disorder Of Lipid Metabolism 33 82.48 Hypertriglyceridemia 12 80.00 Hyperlipidemia 4 79.08 Cv Unclassified Under Development 1 74.76 Acute Coronary Syndrome 1 73.32 Stroke 1 71.40 Myocardial Infarction 2 70.44

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In our opinion, the AIM HIGH and HPS2-THRIVE studies will give us answers to the question whether the combination of simvastatin with niacin ER will reduce residual cardiovascular risk in comparison to statin therapy alone.

Spec (whether) Negative_regulation (reduce) of simvastatin Spec (whether) Binding (combination) of ER

1) Confidence 0.35 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605342 Disease Relevance 1.11 Pain Relevance 0.08

General Comments

This test has worked.